IPO Timeline
Broker Results (T-2)
2020-10-05
Some brokers release in afternoon
Grey Market (T-1)
2020-10-06
Afternoon
HKEX Allotment (T-1)
2020-10-06
Evening
Registrar Allotment (T-1)
2020-10-06
Evening
Listing Day (T)
2020-10-07
First day of trading
Company Overview
| Stock Name | 嘉和生物藥業(開曼)控股有限公司 - B |
|---|---|
| Stock Code | 06998 |
| Company Full Name | 嘉和生物藥業(開曼)控股有限公司 - B |
| Industry | 醫療保健 |
| Principal Activities | 主要於中國從事生物制藥業務，專注於腫瘤及自身免疫藥物的研發及商業化。 |
| Listing Date | 2020-10-07 |
| Listing Rules Era | Old Rules |
| Listing Rules Chapter | To be extracted |
| Weighted Voting Rights (WVR) | No |
| Registered Address (Mainland China) | 香港皇后大道東248號大新金融中心40樓 |
| Business Address (Hong Kong) | To be extracted |
| Place of Incorporation | To be extracted |
| Listing Method | To be extracted |
| Listing Board | Main Board |
| Website | http://www.eddingpharm.com |
| Share Registrar | 卓佳证券登记有限公司 (Tricor Investor Services Limited) |
| Registrar Contact | (852)2862 8628 |
| A-Share/US Dual Listing | No data |
Offering Information
| Offering Mechanism | To be extracted |
|---|---|
| Offer Price | HK$ 24.00 / shares |
| Offer Price Range | To be extracted |
| Lot Size | To be extracted |
| Entry Threshold | To be extracted |
| Par Value | To be extracted |
| Offer Period | To be extracted |
| Global Offering Shares | To be extracted |
| HK Public Offer Shares (Initial) | To be extracted |
| Public Offer Lots (Initial) | To be extracted |
| International Placing Shares (Initial) | To be extracted |
| Offer Ratio | To be extracted |
| Total Shares Post-IPO | To be extracted |
| Greenshoe (Over-allotment Option) | To be confirmed |
| Stabilizing Manager (Greenshoe) | — |
| Cornerstone Share | 50.0% |
| Clawback Tiers | To be extracted |
| Reallocation Option | To be confirmed |
| Total Global Offering Size | HK$ 1,438,584,000 |
Valuation & Financials
| Market Cap (at Offer Price) | To be extracted |
|---|---|
| Pre-IPO Valuation (Last Round) | To be extracted |
| P/E Ratio | To be extracted |
| Profit/Loss Status | To be extracted |
| Period-End Cash Balance | To be extracted |
| Listing Expenses | To be extracted |
| Listing Expenses / Funds Raised | To be extracted |
| Total Pre-IPO Investment | To be extracted |
First Day Performance
| First Day Close | HK$ 27.95 |
|---|---|
| First Day Open | HK$ 29.2 |
| First Day Change | 16.46% |
| First Day Volume | 98372000.0 |
| First Day Turnover | 3027080000.0 |
Use of Proceeds
| Use of Proceeds | 1、所得款項凈額的42%，或約1,131.4百萬港元，用于為我們核心產品的研發活動提供資金； 2、所得款項凈額的23%，或約619.6百萬港元，用于為我們其他主要產品的研發活動提供資金； 3、所得款項凈額的15%或約404.1百萬港元，用于撥付我們管線中其他候選藥物正在進行及計劃進行的臨床試驗、適應癥擴展及注冊備案籌備； 4、所得款項凈額的10%或約269.4百萬港元，用于為我們的藥物管線擴展提供資金； 5、所得款項凈額的10%或約269.4百萬港元作一般企業用途。 |
|---|
Underwriting Syndicate
Joint Sponsors (3)
高盛（亚洲）有限责任公司 CE ACC536
J.P. Morgan Securities (Far East) Limited CE AAB026
富瑞金融集团香港有限公司 CE ATS546
Overall Coordinators (3)
高盛（亚洲）有限责任公司 CE ACC536
J.P. Morgan Securities (Asia Pacific) Limited CE AAJ321
富瑞金融集团香港有限公司 CE ATS546
Joint Bookrunners (7)
高盛（亚洲）有限责任公司 CE ACC536
J.P. Morgan Securities (Asia Pacific) Limited CE AAJ321
富瑞金融集团香港有限公司 CE ATS546
招银国际融资有限公司 CE AVM940
华兴证券（香港）有限公司 CE AZX839
海通国际证券有限公司 CE AAF806
麦格理资本股份有限公司 CE AAC534
Joint Lead Managers (7)
高盛（亚洲）有限责任公司 CE ACC536
J.P. Morgan Securities (Asia Pacific) Limited CE AAJ321
富瑞金融集团香港有限公司 CE ATS546
招银国际融资有限公司 CE AVM940
华兴证券（香港）有限公司 CE AZX839
海通国际证券有限公司 CE AAF806
麦格理资本股份有限公司 CE AAC534
Cornerstone Investors
| # | Investor Name | Investment Amount | Shares Subscribed | % of Offer Shares | % of Total Shares | Lock-up Period | Est. Unlock Date |
|---|---|---|---|---|---|---|---|
| 1 | 3W Funds | 38,460,000 HKD | — | 1.34% | — | 6 months | 2021-04-07 |
| 2 | Aranda Investments Pte. Ltd. | 153,864,000 HKD | — | 5.35% | — | 6 months | 2021-04-07 |
| 3 | Athos Asia Event Driven Master Fund | 38,460,000 HKD | — | 1.34% | — | 6 months | 2021-04-07 |
| 4 | HHJH Holdings Limited | 269,256,000 HKD | — | 9.36% | — | 6 months | 2021-04-07 |
| 5 | Logos Global Master Fund LP | 76,920,000 HKD | — | 2.67% | — | 6 months | 2021-04-07 |
| 6 | Matrix Partners | 153,864,000 HKD | — | 5.35% | — | 6 months | 2021-04-07 |
| 7 | OrbiMed Funds | 192,324,000 HKD | — | 6.68% | — | 6 months | 2021-04-07 |
| 8 | PA Investment Funds SPC－ PA Special Opportunities Fund II SP | 76,920,000 HKD | — | 2.67% | — | 6 months | 2021-04-07 |
| 9 | Tudor Systematic Tactical Trading L.P. | 76,920,000 HKD | — | 2.67% | — | 6 months | 2021-04-07 |
| 10 | 太平洋资产管理有限责任公司 | 153,864,000 HKD | — | 5.35% | — | 6 months | 2021-04-07 |
| 11 | 万通保险国际有限公司 | 38,460,000 HKD | — | 1.34% | — | 6 months | 2021-04-07 |
| 12 | 香港泰格健康科技有限公司 | 169,248,000 HKD | — | 5.88% | — | 6 months | 2021-04-07 |
Directors & Management
| Chairman | 倪昕 |
|---|---|
| Company Secretary | 葉翠媚,王千惠 |
No director data available.
Major Shareholders
| Major Shareholders & Holdings | 高瓴資本管理有限公司(25.33%);云南沃森生物技術股份有限公司(7.43%);淡馬錫控股(私人)有限公司(6.17%) |
|---|
IPO Timeline
